table of content
1 Postmenopausal Vaginal Atrophy Drugs Market Overview
1.1 Product Overview and Scope of Postmenopausal Vaginal Atrophy Drugs
1.2 Postmenopausal Vaginal Atrophy Drugs Segment by Type
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Comparison by Type (2023-2029)
1.2.2 Vaginal Gels
1.2.3 Creams
1.2.4 Tablets
1.2.5 Rings
1.2.6 Patches
1.3 Postmenopausal Vaginal Atrophy Drugs Segment by Application
1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Comparison by Application: (2023-2029)
1.3.2 Offline Stores
1.3.3 Online Stores
1.4 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2018-2029
1.4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2018-2029
1.4.3 Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
2 Postmenopausal Vaginal Atrophy Drugs Market Competition by Manufacturers
2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturers (2018-2023)
2.4 Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Sites, Area Served, Product Type
2.5 Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation and Trends
2.5.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue
2.5.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario by Region
3.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2018-2023
3.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2018-2023
3.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.3.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
3.3.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.4.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
3.4.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
3.5.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.6.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
3.6.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
3.7.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Analysis by Type
4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2018-2023)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2018-2023)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2018-2023)
5 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Analysis by Application
5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2018-2023)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2018-2023)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2018-2023)
6 Key Companies Profiled
6.1 Actavis plc
6.1.1 Actavis plc Corporation Information
6.1.2 Actavis plc Description and Business Overview
6.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.1.5 Actavis plc Recent Developments/Updates
6.2 Bionovo, Inc.
6.2.1 Bionovo, Inc. Corporation Information
6.2.2 Bionovo, Inc. Description and Business Overview
6.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.2.5 Bionovo, Inc. Recent Developments/Updates
6.3 Endoceutics, Inc.
6.3.1 Endoceutics, Inc. Corporation Information
6.3.2 Endoceutics, Inc. Description and Business Overview
6.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.3.5 Endoceutics, Inc. Recent Developments/Updates
6.4 Novo Nordisk A/S
6.4.1 Novo Nordisk A/S Corporation Information
6.4.2 Novo Nordisk A/S Description and Business Overview
6.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.4.5 Novo Nordisk A/S Recent Developments/Updates
6.5 Pfizer Inc.
6.5.1 Pfizer Inc. Corporation Information
6.5.2 Pfizer Inc. Description and Business Overview
6.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.5.5 Pfizer Inc. Recent Developments/Updates
6.6 Teva Pharmaceuticals Ltd.
6.6.1 Teva Pharmaceuticals Ltd. Corporation Information
6.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
6.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.6.5 Teva Pharmaceuticals Ltd. Recent Developments/Updates
6.7 Therapeutics MD, Inc.
6.6.1 Therapeutics MD, Inc. Corporation Information
6.6.2 Therapeutics MD, Inc. Description and Business Overview
6.6.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.7.5 Therapeutics MD, Inc. Recent Developments/Updates
6.8 Shionogi & Company
6.8.1 Shionogi & Company Corporation Information
6.8.2 Shionogi & Company Description and Business Overview
6.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.8.5 Shionogi & Company Recent Developments/Updates
6.9 Allergan plc
6.9.1 Allergan plc Corporation Information
6.9.2 Allergan plc Description and Business Overview
6.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.9.5 Allergan plc Recent Developments/Updates
6.10 Shionogi & Co. Ltd.
6.10.1 Shionogi & Co. Ltd. Corporation Information
6.10.2 Shionogi & Co. Ltd. Description and Business Overview
6.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.10.5 Shionogi & Co. Ltd. Recent Developments/Updates
7 Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Analysis
7.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
7.4 Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Postmenopausal Vaginal Atrophy Drugs Distributors List
8.3 Postmenopausal Vaginal Atrophy Drugs Customers
9 Postmenopausal Vaginal Atrophy Drugs Market Dynamics
9.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
9.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers
9.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
9.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints
10 Global Market Forecast
10.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Postmenopausal Vaginal Atrophy Drugs by Type (2023-2029)
10.1.2 Global Forecasted Revenue of Postmenopausal Vaginal Atrophy Drugs by Type (2023-2029)
10.2 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Postmenopausal Vaginal Atrophy Drugs by Application (2023-2029)
10.2.2 Global Forecasted Revenue of Postmenopausal Vaginal Atrophy Drugs by Application (2023-2029)
10.3 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Postmenopausal Vaginal Atrophy Drugs by Region (2023-2029)
10.3.2 Global Forecasted Revenue of Postmenopausal Vaginal Atrophy Drugs by Region (2023-2029)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
